KalVista Pharmaceuticals, Inc.

KALV

US4834971032

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 19:25:41 16/07/2024 BST			5-day change	1st Jan Change
15.21 ^USD	+1.67%		+24.67%	+24.98%

07-12	Needham Adjusts Price Target on KalVista Pharmaceuticals to $32 From $35, Maintains Buy Rating	MT
07-11	KalVista Pharmaceuticals Files $300 Million Mixed Shelf	MT

KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended April 30, 2024

July 11, 2024 at 09:11 pm

KalVista Pharmaceuticals, Inc. reported earnings results for the fourth quarter and full year ended April 30, 2024. For the fourth quarter, the company reported net loss was USD 44.65 million compared to USD 26.31 million a year ago. Basic loss per share from continuing operations was USD 1.02 compared to USD 0.77 a year ago.
For the full year, net loss was USD 126.64 million compared to USD 92.91 million a year ago. Basic loss per share from continuing operations was USD 3.44 compared to USD 3.33 a year ago.

Latest news about KalVista Pharmaceuticals, Inc.

Needham Adjusts Price Target on KalVista Pharmaceuticals to $32 From $35, Maintains Buy Rating	07-12	MT
KalVista Pharmaceuticals Files $300 Million Mixed Shelf	07-11	MT
KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended April 30, 2024	07-11	CI
KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended April 30, 2024	07-11	CI
KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) added to Russell 3000 Growth Index	06-30	CI
KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) dropped from Russell Microcap Value Index	06-30	CI
KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) dropped from Russell 3000E Value Index	06-30	CI
KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) dropped from Russell 3000 Value Index	06-30	CI
KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) dropped from Russell 2500 Value Index	06-30	CI
KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) dropped from Russell Small Cap Comp Value Index	06-30	CI
KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) added to Russell Microcap Growth Index	06-30	CI
KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) dropped from Russell 2000 Value Index	06-30	CI
KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) added to Russell 3000E Growth Index	06-30	CI
KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) added to Russell 2000 Growth Index	06-30	CI
KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) added to Russell 2500 Growth Index	06-30	CI
KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) added to Russell Small Cap Comp Growth Index	06-30	CI
KalVista Starts Hereditary Angioedema Trial in Pediatric Patients	06-27	MT
KalVista Pharmaceuticals, Inc. Initiates KONFident-KID Trial for On-Demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11	06-27	CI
KalVista Pharmaceuticals Submits New Drug Application to FDA for Investigational Hereditary Angioedema Treatment	06-18	MT
KalVista Seeks FDA OK of Sebetralstat for Hereditary-Angioedema Attacks	06-18	DJ
KalVista Pharmaceuticals, Inc. Submits New Drug Application to FDA for Sebetralstat as First Oral On-Demand Treatment for Hereditary Angioedema	06-18	CI
KalVista Pharmaceuticals, Inc. Presents Data At Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024	06-06	CI
Kalvista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema At the European Academy of Allergy and Clinical Immunology Congress 2024	06-03	CI
Sector Update: Health Care Stocks Higher Late Afternoon	05-31	MT
Sector Update: Health Care	05-31	MT

Chart KalVista Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting the disease hereditary angioedema (HAE). The Company is developing sebetralstat as an oral on-demand therapy for HAE attacks and has achieved target enrollment for the phase 3 KONFIDENT clinical trial. The Company is also conducting preclinical development on oral Factor XIIa (Factor XIIa) inhibitor program, which is advancing to provide the next generation of HAE therapeutics. It is also focused on development of oral plasma kallikrein inhibitors for HAE and Factor XIIa inhibitors for HAE and other indications. Plasma kallikrein is a serine protease enzyme that is a key mediator of inflammation and edema.

Sector

Pharmaceuticals

Calendar

04/09/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

14.96 USD

Average target price

29.2 USD

Spread / Average Target

+95.19%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
KALVISTA PHARMACEUTICALS, INC.	+24.98%	639M
CSL LIMITED	+7.40%	101B
SAMSUNG BIOLOGICS CO.,LTD.	+8.42%	42.18B
BIOGEN INC.	-13.26%	32.26B
UCB	+80.80%	29.79B
BIOMARIN PHARMACEUTICAL INC.	-11.61%	16.06B
INCYTE CORPORATION	+1.80%	14.45B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-6.77%	12.01B
ALTEOGEN INC.	+177.16%	10.71B
SWEDISH ORPHAN BIOVITRUM AB	+4.12%	8.89B

Biopharmaceuticals